LPA (lysophosphatidic acid) is a lipid mediator that stimulates cell proliferation and growth, and is involved in physiological and pathological processes such as wound healing, platelet activation, angiogenesis and the growth of tumours. Therefore defining the mechanisms of LPA production and degradation are of interest in understanding the regulation of these processes. Extracellular LPA synthesis is relatively well understood, whereas the mechanisms of its degradation are not. One route of LPA degradation is dephosphorylation. A candidate enzyme is the integral membrane exophosphatase LPP1 (lipid phosphate phosphohydrolase type 1). In the present paper, we report the development of a mouse wherein the LPP1 gene (Ppap2a) was disrupted. The homozygous mice, which are phenotypically unremarkable, generally lack Ppap2a mRNA, and multiple tissues exhibit a substantial (35-95 %) reduction in LPA phosphatase activity. Compared with wild-type littermates, Ppap2a tr/tr animals have increased levels of plasma LPA, and LPA injected intravenously is metabolized at a 4-fold lower rate. Our results demonstrate that LPA is rapidly metabolized in the bloodstream and that LPP1 is an important determinant of this turnover. These results indicate that LPP1 is a catabolic enzyme for LPA in vivo.
INTRODUCTION
LPA (lysophosphatidic acid; 1-acyl-2-lyso-sn-glycero-3-phosphate) has long been known as an intermediate in de novo biosynthesis of all glycerophospholipids. LPA gained credence as a signalling molecule with the discovery in the early 1990s by Moolenaar and collaborators that LPA promotes cell proliferation (see [1] for a review). LPA and other biologically active lipid phosphates, notably S1P (sphingosine 1-phosphate), have since been studied extensively and found to have a role as mediators in a variety of physiological and pathological processes. The stimulatory effect of LPA on cell proliferation, survival and migration serves as the underlying mechanism of the major biological effects of LPA. The most conspicuous examples are the involvement of LPA in wound healing, platelet activation, vascular remodelling and the progression of some forms of cancer such as ovarian tumours (see [2] for a review).
The role of LPA and other lipid phosphates as first messengers was firmly established by the realization that many of the biological effects of these molecules are mediated by their interaction with specific seven-transmembrane-domain G-proteincoupled receptors (see [3] for a review). As with any bona fide signalling molecule, specific mechanisms are expected to exist that ensure its timely destruction to prevent the detrimental effects of overstimulation. LPA catabolism is presumed to be mediated by a group of phosphatases termed lipid phosphate phosphohydrolases (LPPs) rather than phosphatidate phosphatases (lipins) that are specific for phosphatidate [4, 5] .
LPPs [formerly known as PAPs (phosphatidic acid phosphatases) (see [6, 7] for reviews)] are enzymes that catalyse the hydrolysis of a variety of lipid phosphate mono-esters. The LPPs are Mg 2+ -independent and NEM (N-ethylmaleimide)-insensitive (LPP1, LPP2 and LPP3 formerly known as PAP2A, PAP2B and PAP2C respectively; see [8] for a review). LPP1-LPP3 are cellsurface N-glycosylated integral membrane proteins. LPP3 in some cell types also localizes to intracellular membranes [9] . The topology of membrane LPPs is such that the active-site amino acids are exofacial, thus these enzymes function as exophosphatases [10] .
The hypothesis that one or more LPP isotype may function to delimit LPA signalling has been difficult to test. On the one hand, LPP1 and LPP3 are nearly ubiquitous among mammalian cells (see [11] for a review) and forced expression of these proteins is either toxic to cells or provides information restricted to cells in culture under somewhat artificial conditions [12, 13] . On the other hand, the difficulties inherent in the study of integral membrane proteins (a lack of quality antibodies and purified protein) have slowed progress in understanding these enzymes. A chemical biology approach has not been particularly informative in that selective inhibitors have yet to be developed, and structureactivity relationship of substrates is rather uninformative. That is, the LPP isotypes act on a wide variety of lipid monophosphates, including LPA, PA (phosphatidic acid), diacylglycerolpyrophosphate, S1P and ceramide 1-phosphate. Using in vitro assays, LPP1 exhibits a preference for glycerol over sphingoid-basecontaining lipids, whereas LPP3 does not differentiate as well among these substrates (see [10] for a review). These ectoactivities of LPP1 have two potentially important functions. First, they could regulate circulating concentrations of LPA or S1P and thus the activation of their respective receptors. Decreased LPP activities occur in tumours, and this has been proposed as a mechanism that results in increased LPA-induced growth in ovarian cancers [14] . Secondly, the dephosphorylated product formed by the LPP is taken up by the cell and thereby it stimulates cell signalling itself or after rephosphorylation. [5, 6, 15, 16] .
An alternative approach (genetic manipulation) has yielded several studies reporting the consequences of altering the expression of LPP genes. Disruption of the mouse gene encoding LPP3 (Ppap2b) is embryonic lethal [at E9.5 (embryonic day 9.5)], apparently as a consequence of aberrant embryonic and extra-embryonic development of the vasculature [17] . In contrast, mice lacking LPP2 (Ppap2c −/− ) are viable, fertile and not noticeably different from wild-type littermates [18] . Ablation of the Drosophila homologues of the mammalian LPPs (Wun and Wun2) results in a defect in germ cell migration, suggesting that a spatial pattern of phospholipid hydrolysis is required for the migration and survival of germ cells during fruitfly development [19] . Global forced expression of LPP1 (Ppap2a) in mice resulted in runted animals with fur abnormalities and impaired spermatogenesis, a phenotype that is not readily ascribed to increased extracellular LPA or PA degradation. Interestingly, these LPP1 transgenic mice had normal levels of plasma LPA [20] .
In the present paper, we report the generation and characterization of a mouse strain wherein the gene encoding LPP1 (Ppap2a) is disrupted by insertion of an exon-trapping element. Mice with one (Ppap2a +/tr ) or both (Ppap2a tr/tr ) alleles disrupted are viable and fertile. We used these mice as an in vivo model to establish whether LPP1 plays a physiological role in controlling the degradation of circulating LPA. Our results demonstrate that LPP1 performs this function in vivo.
EXPERIMENTAL

Generation of LPP1-null mice
An ES (embryonic stem) cell line (RRD231) reported to harbour a gene-trap vector (pGT1Lxf) in the first intron of the Ppap2a gene was obtained from BayGenomics via the Mutant Mouse Regional Resource Center (MMRRC) at Davis, CA, U.S.A. We verified the presence of the trapping element and established further its precise location by sequencing genomic DNA from Ppap2a tr/tr mice (see Figure 1 ). Chimaeric founder mice were generated at the University of Virginia Transgenic Mouse Facility using C57BL/6 blastocysts. The ES cells were sv129 strain, and animals used in the present study were of mixed genetic background (F1N1, F1N5).
Genotyping of mice
Mice were genotyped by PCR using genomic DNA from tail biopsies, liver or brain samples and the following primers (see Figure 1 ): 5 -GAGAGTGAGCGAGTGTCTGAGTTTCTG-ATG-3 (forward), 5 -AGTACTGGGCATCTCACACCACAT-3 (reverse wild-type allele) and 5 -CCTTCAAAGGGAAGGGG-TAAAGTGGTAGGG-3 (reverse trapped allele).
Amplification in the presence of 20 ng of DNA and 4 mM MgCl 2 was carried out as follows: 94
• C for 3 min, followed by 35 cycles at 94
• C (30 s), 57
• C (1 min), 72
• C (1.5 min), and a final 72
• C step for 10 min.
Real-time RT (reverse transcription)-PCR
RNA was extracted from tissues and cDNA was obtained using the SuperScript First-Strand Synthesis System (Invitrogen) using random hexamers according to the manufacturer's instructions. Amplification was performed in an iCycler iQ 2). Mice used in the present study harbour an exon-trapping element ('Exon Trap') between exons 1 and 2 and therefore generate a truncated mRNA ('Trapped Ppap2a') consisting of exon 1 spliced to the coding sequence of the trapping element followed by a poly(A) sequence. Because insertion occurred upstream of exons 2, only one trapped isoform exists. The exact location of the trapping element was determined by genomic DNA sequencing and found to be some 25 600 bp downstream of the 5 end of the gene (approx. 75 % the length of intron 1). The sequence at the insertion point shows an intervening 5 nt sequence of unknown origin ('unk') between the Ppap2a gene and the trap element sequence ('pGT1Lxf'). Genotyping was carried out by PCR amplification of genomic DNA using a forward primer complementary to a sequence upstream of the insertion point, and two reverse primers corresponding to sequences downstream in the normal and in the trapped gene. Expected products sizes were 675 and 931 bp for the normal and trapped genes respectively. (B) Analysis of PCR products by agarose gel electrophoresis for homozygous (Ppap2a tr/tr , 'HO'), heterozygous (Ppap2a +/tr , 'HE') and wild-type (Ppap2a +/+ , 'WT') animals using the indicated combinations of forward and reverse primers. In (A), the relative positions of the exons and the trap element are shown according to their actual locations within the gene; exon sizes, however, have been exaggerated for clarity (they constitute only approx. 2 % of the gene).
System (Bio-Rad Laboratories) at 95
• C for 4 min, followed by 40 cycles at 95
• C, 55
• C and 72
• C (30 s each step) in 50 μl of a SYBR Green-based medium (iQ SYBR Green Supermix; Bio-Rad Laboratories) using the following forward and reverse primers: 5 -TGTACTGCATGCTGTTTGTCGCAC-3 and 5 -TGACGTCACTCCAGTGGTGTTTGT-3 for LPP1; and 5 -ATAAACGATGCTGTGCTCTGTGCG-3 and 5-TTTGC-TGTCTTCTCCTCTGCACCT-3 for LPP3. The levels of mRNA expression were normalized to the expression level of the 18S rRNA gene measured using a commercial primer kit (QuantumRNA, Classic II; Ambion). Quantitative gene expression was obtained from cycle differences at appropriate thresholds and the efficiency of amplification as described by Pfaffl [21] . The size and singularity of the RT-PCR products was established by agarose gel electrophoresis and melting point analysis. For the detection of the different LPP1 isoforms, a similar protocol was followed, but using the following forward and reverse primers: 5 -ATCCATTTCAGAGGGGCTTT-3 and 5 -AACCTGCCCTCCTTGACTTT-3 for isoform 1; and 5 -TT-CAAGGCATACCCCCTTC-3 and 5 -GGTGGCTATGTAGG-GATTGC-3 for isoform 2. To amplify the cDNA region containing the trap insertion point in intron 2, a similar protocol was used except for annealing at 53
• C and the use of the 5 -TC-TGTTCCTCCCGCCACT-3 primer in conjunction with the reverse primer used for LPP1 isoform 1. 
Measurement of LPP activity in tissue homogenates
Mice were anaesthetized with isofluorane [2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane] and killed by cervical dislocation. Organs were obtained immediately, frozen in liquid nitrogen and stored at − 80 • C. Brain samples consisted of tissue from the cerebral hemispheres. Skeletal muscle samples were obtained from the hind legs. Frozen tissue samples were homogenized using a motor-driven Teflon pestle homogenizer in 10 vol. of 20 mM Tris/HCl (pH 7.5), 1 mM EGTA, 1 mM PMSF, 1 mM DTT (dithiothreitol), 10 μg/ml aprotinin (Sigma) and 10 μg/ml leupeptin (Sigma). Homogenates were centrifuged at 500 g for 15 min and the supernatant fluids were divided into 250 μl aliquots and stored at − 80
• C (pellets were discarded). The protein content of these preparations was measured according to the method of Bradford [23] using a commercial Coomassie Blue solution (Bio-Rad Laboratories). LPP activity was measured as the release of [ 32 P]H 3 PO 4 from 32 P-labelled substrates presented as mixed Triton X-100 micelles as described previously [24] with some modifications. Assays were carried out in 200 μl of a buffer consisting of 20 mM Tris/HCl (pH 7.5), 1 mM MgCl 2 , 1 mM DTT, 3.2 mM Triton X-100, 100 μM LPA or PA and 50 000 d.p.m. of [ 32 P]LPA or [ 32 P]PA. Assays were carried out at 37
• C in the presence of 100 μg of protein for different times (5-30 min), according to the specific LPP activity of each tissue so that degradation did not exceed 5 % of the total substrate. Different incubation times were preferred over incubation with different amounts of protein to preserve the Triton X-100/protein content ratio. Reactions were started by mixing 100 μl of mixed micelles with 100 μl of a solution containing the remaining components. Activity was constant with time for every tissue. No LPP activity was observed in absence of tissue. Reactions were stopped by adding 200 μl of 1 M HClO 4 containing 100 μM phosphoric acid. Samples were then centrifuged at 15 000 g for 5 min, and the supernatant was extracted twice with watersaturated butan-1-ol. Orthophosphate was recovered from the extracted aqueous phase as described in [25] by precipitation with 12.5 mM ammonium molybdate and extraction with isobutanol (2-methylpropan-1-ol)/benzene (1:1, v/v). Radionuclide in the organic phase was measured by liquid-scintillation spectrometry. Specific activity of the substrates was determined by measuring the amount of 32 P present in known volumes of reaction medium. To measure the NEM-sensitive Mg 2+ -independent activity, tissue samples containing 100 μg of protein were brought to 80 μl and supplemented with 10 μl of 50 mM NEM. After a 15 min incubation, NEM was neutralized by adding 10 μl of 22 mM DTT (1 mM final DTT). This solution was then added to 100 μl of mixed micelles and processed as described above, except for the omission of MgCl 2 and the addition of 1 mM EGTA and 2 mM EDTA [26] .
Measurement of the LPP activity of tissue slices and splenocytes
Ppap2a
+/+ and Ppap2a tr/tr mice were anaesthetized with isofluorane and killed by cervical dislocation. The brain hemispheres, kidney, liver and spleen were removed, placed in ice-cold buffer A (140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 5 mM glucose and 20 mM Hepes/NaOH, pH 7.4) and sliced into 300-μm-thick slices using a Vibratome type slicer (Dosaka DTK 1500E microslicer). Slices were trimmed to approx. 3 mm × 3 mm squares and incubated in 200 μl of buffer A containing 0.1 % FAF-BSA (fatty-acid-free BSA) (Sigma), 100 μM LPA and approx. 2 × 10 5 c.p.m. of [ 32 P]LPA for various times at 37 • C. At the end of the incubation periods, 100 μl aliquots were withdrawn, and the presence of [ 32 P]H 3 PO 4 was assayed as described above for tissue homogenates. The remaining 100 μl were discarded, the tissue was dissolved in 2 % (w/v) SDS, and the protein content measured using the bicinchonic acid method using a commercial kit (Pierce). Activity was linear with time. Linearity with protein concentration was tested only for slices of the same thickness and roughly the same size and shape. In particular, we carried out incubations with half, one or two 3 mm × 3 mm slices and found that activity and protein were linearly correlated. For slices of different thickness, activity and protein were not linearly correlated, therefore, and to ensure thickness homogeneity, similar organs from Ppap2a +/+ and Ppap2a tr/tr mice were mounted together and sliced simultaneously. Splenocytes were obtained by passing the spleens through a nylon cell strainer (100 μm mesh; Falcon) and discarding the capsule. Cells were resuspended in 1 ml of buffer A and centrifuged at 300 g for 5 min. The pellet was resuspended in 1 ml of erythrocyte lysis buffer (8.29 g/l NH 4 Cl, 1 g/l KHCO 3 and 0.0372 g/l Na 2 EDTA, pH 7.3) and incubated on ice for 5 min. Lysis was quenched by adding 9 ml of buffer A and washing the cell preparation twice (at 300 g for 5 min each). Finally, cells were resuspended in 1 ml of buffer A and counted using a haemocytometer. Viability, assessed by Trypan Blue exclusion, was >99 %. LPP activity was measured as described above and started by resuspending pellets (300 g for 5 min) containing 5 × 10 5 lysed or non-lysed cells (approx. 100 and 20 μg of protein respectively) in 200 μl of reaction medium. In both cases, slices and splenocytes, incubation times were identical for similar tissues from Ppap2a +/+ and Ppap2a tr/tr mice and they were adjusted for substrate degradation not to exceed 5 %. No release of [ 32 P]H 3 PO 4 was observed in the absence of slices or cells.
Measurement of plasma LPA concentration
Plasma was obtained by cardiac puncture using EDTA (∼ 5 mM) as anticoagulant. LPA levels were determined by LC (liquid chromatography)-MS/MS (tandem MS) using a hybrid ABI-4000 triple quadrupole-ion-trap mass spectrometer (Applied Biosystems) coupled with an Agilent 1100 LC column and C 17:0 LPA as an internal standard [27] . LPA species were separated on a Zorbax Eclipse XDB-C 8 HPLC column (4.6 mm × 150 mm, 5 μm particle size) using methanol/water/methanoic (formic) acid, 79:20:0.5 (by vol.) as solvent A and 99:0.5:0.5 (by vol.) as solvent B, containing in both cases 5 mM NH 4 COOH. Elution was carried out in solvent A for 1 min. A gradient change to solvent B lasting 1 min was then effected and a final isocratic elution of LPA was carried out in solvent B for 7 min. LPA species were analysed in negative-ionization mode with declustering potential and collision energy optimized for C 17 
Preparation of plasma for clearance studies
A series of Ppap2a +/+ and Ppap2a tr/tr mice were anaesthetized and exsanguinated by cardiac puncture using EDTA (∼ 5 mM) as anticoagulant. Plasma was prepared as described previously [28] by centrifuging the blood twice, at 1000 and 10 000 g for 3 min each time at 4
• C, and stored at − 80 • C. Aliquots (200 μl) of these plasma preparations were used as a vehicle for [ 32 P]LPA to study LPA clearance as described below. Plasma used in clearance experiments was in each case of the same genotype as the animals whose clearance was being investigated.
Measurement of LPA clearance in vitro
Blood samples from a series of Ppap2a +/+ and Ppap2a tr/tr mice were obtained and anticoagulated with EDTA (∼ 5 mM). Half of these samples were used as whole blood and the other half were used as plasma (obtained as described above). Blood and plasma samples were supplemented as soon as they were obtained with • C, [ 32 P]LPA was measured as follows: plasma samples and plasma obtained from blood samples as described above were immediately acidified with 3.33 vol. of ice-cold 30 mM citric acid and 40 mM Na 2 HPO 4 (pH 4.0), and extracted twice with 8.88 vol. of water-saturated butan-1-ol. Butan-1-ol extractions were then combined, dried under a stream of N 2 , redissolved in chloroform and subjected to TLC as described above. Radioautographic analysis of the developed plates showed only one band that comigrates with authentic LPA (R f = 0.5). LPA was then measured by scraping off the LPA bands from the developed TLC plates and measuring their 32 P content by liquid-scintillation spectrometry. The zero time plasma samples were also used to assess the quantitative recovery of LPA from plasma by comparing the amount of [ 32 P]LPA added to the plasma samples with the amount of [ 32 P]LPA recovered from TLC plates. Similar to the 99 % recovery value reported previously for this technique [29] , our recovery was not significantly different from 100 %.
Measurement of LPA clearance in vivo
Mice (24-27 g) were anaesthetized with methoxyfluorane (2,2-dichloro-1,1-difluoro-1-methoxyethane) and injected through the tail vein with approx. 10 8 c.p.m. of [ 32 P]LPA (6.5 × 10 − 12 mol) dissolved in 150 μl of either plasma (see above) or sterile saline (0.9 % NaCl) containing 0.1 % FAF-BSA. Immediately after injection, a blood sample (three to six drops or approx. 50-100 μl) was taken by retro-orbital bleeding using a microhaematocrit capillary tube and EDTA (∼ 5 mM) as anticoagulant. This first sample was obtained approx. 2-3 min after injection and it was considered to be the zero time sample. Additional samples were taken at 5, 15 and 30 min. Immediately after they were obtained, blood samples were processed as described above to measure plasma [
32 P]LPA. Similar to the in vivo experiments, no band other than LPA was observed by radioautography.
Measurement of lysoPLD (lysophospholipase D) activity
Plasma lysoPLD activity was measured according to UmezuGoto et al. [30] by mixing 10 μl of plasma with 90 μl of a buffer consisting of 100 mM Tris/HCl (pH 9.0), 500 mM NaCl, 5 mM MgCl 2 , 30 μM CoCl 2 , 0.05% Triton X-100 and 1.1 mM LPC (lysophosphatidylcholine) (Avanti Polar Lipids). After 4 h of incubation at 37
• C, choline in samples was measured colorimetrically at 555 nm by adding 100 μl of 50 mM Tris/HCl (pH 8.0), 5 mM MgCl 2 , 50 units/ml horseradish peroxidase, 18 units/ml choline oxidase, 5 mM 4-aminoantipyrine and 3 mM N-ethyl-N-(2-hydroxy-3-sulfopropyl) -m-toluidine. Net production of choline was calculated by subtracting the amount of choline present in parallel samples that were kept frozen. Blood was obtained by retro-orbital bleeding using heparin as anticoagulant. Choline chloride (Fluka) was used as standard.
Animal care
The University of Virginia's Animal Care and Use Committee approved all experiments with animals.
RESULTS
Generation of Ppap2a
+/+ , Ppap2a +/tr and Ppap2a tr/tr mice
We first established the exact location of the exon trap element by sequencing genomic DNA from Ppap2a tr/tr mice. As shown in Figure 1(A) , insertion occurred in intron 1 as reported by BayGenomics. Mouse LPP1 is expressed as two different isoforms as a result of alternative splicing of exon 2 [31] . However, in the present instance, both variants were expected to be trapped because insertion occurred upstream of either exon 2 ( Figure 1A ). On the basis of the location of the trap element, we designed primers to detect by PCR the normal and trapped versions of the gene and were able to identify wild-type, heterozygous and homozygous animals or Ppap2a +/+ , Ppap2a +/tr and Ppap2a tr/tr animals ( Figure 1B) . Ppap2a tr/tr and Ppap2a +/tr mice are phenotypically unremarkable, i.e. their anatomy, behaviour and fertility are not readily distinguished from those of wild-type littermates. We examined the gross anatomy of all major organs of these animals and found no differences from wild-type animals. Our examination included the male reproductive tract and the prostate in particular because Ppap2a mRNA is particularly prominent in prostate and Ppap2a is an androgen-induced gene [32] .
Ppap2a mRNA expression
We next investigated the levels of Ppap2a mRNA expression in different organs of Ppap2a tr/tr and Ppap2a +/+ mice by quantitative real-time RT-PCR. In these experiments, primers were anchored to exons 3 and 4 (forward primer) and 5 (reverse primer) and therefore results correspond to the combined expression of both LPP1 isoforms which, as depicted in Figure 1(A) , are generated by alternative splicing of exon 2. As presented in Figure 2 , Ppap2a tr/tr mice exhibited much reduced levels of LPP1 expression in relation to Ppap2a +/+ littermates in all organs studied except the brain. Ppap2a mRNA expression in Ppap2a tr/tr mice ranged from 1/300 (kidney) to 1/800 (muscle) of The expression of Ppap2a (LPP1) and Ppap2b (LPP3) mRNA was measured by real-time RT-PCR in Ppap2a tr/tr and Ppap2a +/+ mice. In the case of LPP1, appropriate primers were used to obtain the combined expression of both isoforms (see Results). mRNA expression for LPP1 (Ppap2a) and LPP3 (Ppap2b) was normalized to the expression of the 18S ribosomal RNA gene. Shown is the expression of mRNA for LPP1 (grey bars) and LPP3 (white bars) as a ratio (Ppap2a tr/tr /Ppap2a +/+ ). Data correspond to the mean + − S.D. of three ratios measured in three different pairs of animals (note the split y-axis). Inset: expression of Ppap2a mRNA in the brain ('B'), liver ('L'), kidney ('K') and spleen ('S') of Ppap2a tr/tr and Ppap2a +/+ mice. In this case, a standard PCR was carried out for 33 cycles using a forward primer anchored to exon 1 and a reverse primer anchored to exons 3 and 4. The expected molecular mass of the PCR product is 531 bp. Sizes are indicated in bp.
the levels found in Ppap2a
+/+ mice. The unaltered expression of Ppap2a mRNA in the brain prompted us to investigate whether these animals lack the trapping element in this organ, but we found no evidence for a wild-type allele in Ppap2a tr/tr mice in brain genomic DNA (results not shown). Furthermore, we found no difference in the expression of Ppap2a mRNA isoforms in comparing brains of Ppap2a tr/tr and Ppap2a +/+ mice (results not shown). Finally, we examined the expression of LPP3 in the same organs and found that, unlike LPP1, levels of LPP3 expression in Ppap2a tr/tr and Ppap2a +/+ mice were similar ( Figure 2 ).
LPA phosphatase activity
Tissue homogenates from Ppap2a tr/tr mice exhibited reduced phosphatase activity in all organs studied except the brain, although the extent of reduction varied among tissues ( Figure 3A ). Using [ 32 P]LPA as a substrate, we observed values ranging from 43 % in heart (i.e. activity in Ppap2a tr/tr mice was 57 % of that of Ppap2a +/+ mice) to 91 % in the spleen. With [ 32 P]PA as a substrate, values ranged from 31 % in the kidney to 88 % in the spleen. We found major differences in LPP activity between the brain and the other organs studied. As predicted from Ppap2a mRNA quantification, LPA phosphohydrolase activity was not diminished in brain tissue from Ppap2a tr/tr mice. We also found that the lipid phosphohydrolase activity from both Ppap2a tr/tr and Ppap2a +/+ mice was higher with PA (compared with LPA) as a substrate in brain homogenates compared with other tissues. In toto, these results lead us to conclude that Ppap2a tr/tr mice are not entirely null for LPP1, rather these animals are LPP1 hypomorphs that exhibit severely reduced expression of Ppap2a mRNA and reduced LPP activity in all organs studied except the brain.
As mentioned in the Introduction, LPPs such as LPP1 are NEMinsensitive and Mg 2+ -independent and act as exophosphatases, 2+ -dependent activity observed in brain ('B'), heart ('H'), kidney ('K'), liver ('Li'), lung ('Lu'), muscle ('M') and spleen ('S') of Ppap2a tr/tr animals is expressed in relation to the activities observed in the corresponding organs of Ppap2a +/+ animals, i.e. the Ppap2a tr/tr /Ppap2a +/+ ratio of NEM-sensitive Mg 2+ -dependent activities.
i.e. they degrade lipids presented to the extracellular face of the cell membrane. A second group of lipid phosphohydrolases have opposite characteristics: they are sensitive to NEM, require Mg 2+ and are located inside the cells. We carried out a series of experiments to map further to LPP1 the reduction of lipid phosphohydrolase activity observed in Ppap2a tr/tr mice. To this end, we investigated first the effects of NEM alkylation and lack of Mg 2+ on our assay of tissue phosphohydrolase activity ( Figure 3A ) and, secondly, the exophosphatase activity of intact tissues ( Figure 4) . As shown in Figure 3(A) , only a small fraction of the total activity was NEM-sensitive. We compared the NEM-sensitive Mg 2+ -dependent fractions from similar organs of Ppap2a tr/tr and Ppap2a +/+ mice and found that, in some cases, Ppap2a tr/tr mice show an increased amount of NEM-sensitive Mg 2+ -dependent activity. This phenomenon is illustrated in Figure 3(B) , where the Ppap2a tr/tr /Ppap2a +/+ ratio of NEM-sensitive Mg 2+ -dependent activities is shown for each organ. In the cases of the kidney, liver and muscle, ratios were much higher than unity: 7.6, 5.9 and 15 respectively. For the other organs studied, values ranged from 0.83 to 1.1.
LPA exophosphatase activity
The topology of LPP1 is such that the active site is at the cell surface, thus we measured exophosphatase activity (Figure 4) . We prepared tissue slices from different organs, incubated them with [ 32 P]LPA and measured the release of [ 32 P]H 3 PO 4 . Similarly to our previous findings with tissue homogenates, Ppap2a tr/tr mice organs, with the exception of the brain, showed a decreased level of exophosphatase activity and, once again, the spleen was the most severely affected organ. Values were 65, 74 and 94 % reduction for the kidney, liver and spleen (Figures 2 and 3) . We examined in more detail the exophosphatase activity of the spleen. Splenocytes isolated from Ppap2a tr/tr mice exhibit, as expected, a greatly reduced exophosphatase activity (>99 %).
Plasma LPA levels
If LPP1 metabolizes LPA in vivo, the reduced levels of LPA phosphohydrolase activity in Ppap2a tr/tr mice should result in elevated levels of plasma LPA. We tested this prediction by measuring plasma LPA levels in Ppap2a tr/tr and Ppap2a +/+ mice using LC-MS/MS. We found that Ppap2a tr/tr mice have higher levels of plasma LPA on average, but there was substantial variation in LPA levels among animals ( Figure 5 ). To determine the source of this variation, we measured plasma LPA levels in a homogeneous population of pure C57BL/6j mice. We found that LPA levels in age-and gender-matched C57BL/6j mice were in agreement with values reported previously (see the Discussion) and exhibited low variability ( Figure 5 ). This result suggests that the observed difference in plasma LPA levels between Ppap2a tr/tr and Ppap2a +/+ mice is genuine and the wide range of LPA plasma values is a reflection of a diverse (genetically as well as age and gender) population. To test this idea, we back-crossed the mutant Ppap2a mice against C57BL/6j mice for four additional generations. After ascertaining that mutant and wild-type F1N5 mice retained the differences in Ppap2a mRNA and activity delineated above, we measured plasma LPA levels. Although the F1N5 mice had much less variation in plasma LPA levels, the difference between Ppap2a tr/tr mice and their wild-type littermates remained ( Figure 5) . Interestingly, the mole fractions of the LPA species measured were not different in Ppap2a tr/tr and Ppap2a 
Degradation of LPA in blood
Next, we examined the ability of Ppap2a tr/tr and Ppap2a +/+ mice to metabolize LPA by measuring the rate of disappearance of [ 32 P]LPA in blood both ex vivo and in vivo. Figure 6 (A) documents that the amount of LPA that can be recovered from whole blood incubated at 37 • C rapidly diminished as a function of time. tr/tr animals show any abnormality in the production of LPA, probably a compensatory reduction as a consequence of the elevated plasma LPA levels and the reduced rate of LPA degradation. We found no differences between Ppap2a +/+ and Ppap2a tr/tr mice when we used a colorimetric method to detect choline produced by the breakdown of LPC into choline and LPA catalysed by plasma lysoPLD. For practical reasons, the first sample could not be obtained earlier than 2-3 min after injections. This first blood sample was considered to be the 'zero time' sample and therefore subsequent samples were taken 5, 15 and 30 min after the moment the first sample was obtained (rather than after the moment of injection). In both cases, ex vivo and in vivo, plasma was immediately obtained from each timed blood sample by centrifugation and then extracted with butan-1-ol under acidic conditions. Butan-1-ol extracts were then analysed by TLC. 
DISCUSSION
In vitro studies have implicated LPP1 in the phosphohydrolysis of extracellular LPA, but the lack of specific inhibitors has made testing the physiological relevance of LPP1 in this process difficult. In the present paper, we document that disruption of the LPP1-encoding gene, Ppap2a, results in mice with substantially reduced NEM-resistant LPA/PA phosphatase activity, moderately elevated plasma LPA levels and slowed clearance of exogenously administered LPA. Our data demonstrate that LPP1 contributes 43-81 % of the total tissue LPA phosphohydrolase activity and 65-99 % of the exophosphatase activity. We suppose that the residual LPA/PA phosphatase activity is due to other lipid phosphatases such as LPP3. Our results support the contention that LPP1 is a physiologically relevant LPA exophosphatase.
Exophosphatase activity was virtually nil in Ppap2a tr/tr splenocytes, suggesting that LPP1 is the only functioning exo-LPP in these cells. This is a somewhat surprising observation in view of the presence of Ppap2b mRNA in splenocytes. Nevertheless, the lack of LPA exophosphatase activity may be exploited to examine the role of LPP1 further. The unaltered level of Ppap2a mRNA expression and enzyme activity in the brains of Ppap2a tr/tr mice was unexpected. The possibility that Ppap2a tr/tr mice lack the trapping element in brain tissue, i.e. mosaicism, was ruled out by genotyping brain DNA. We reasoned that alternative splicing might be responsible for the failure of the exon-trapping element in brain, but we were unable to detect differential expression of known LPP1 isoforms [31] . Thus we do not have a plausible explanation as to why the pre-mRNA splicing machinery does not recognize the exon trap splicing acceptor site in brain.
Our LPP1 hypomorphic mice have elevated plasma LPA levels. The range of reported mouse plasma LPA concentrations is 170-625 nM [33] [34] [35] [36] . The lowest concentration detected in our LPP1 mice was 368 nM, whereas the highest was 2.45 μM ( Figure 5 ). We considered whether the source of this large variation in LPA levels was an artefact of our methods (plasma preparation, LC-MS/MS) or a reflection of the genetic diversity of our LPP1 colony (F1N1, C57BL/6 × sv129 strains). When one of our laboratory groups (that of K.R.L.) generated plasma from age-and gendermatched pure-bred C57BL/6j mice and blinded another of our laboratory groups (that of V.N.) to the source of this plasma, our methods yielded values that were similar to previously reported mouse plasma LPA concentrations and, most importantly, exhibited much less variation: 348 + − 98 nM, i.e. 28 %. Additionally, the intra-assay variability was found to be slight ( Figure 5 ). Thus we reasoned that the disparity in plasma LPA levels measured in our F1N1 Ppap2a tr/tr mice was due largely to differences in genetic background and, perhaps, in gender and age. When our LPP1 mouse colony was re-derived at F1N5 after additional crossings on to the C57Bl/6j background, the variability in plasma LPA levels was substantially reduced in age-matched mice ( Figure 5 ). Nonetheless, our data indicate consistently that LPP1-deficient mice exhibit plasma LPA levels significantly higher than control littermates, supporting the hypothesis that LPP1 acts as an LPA exophosphatase. Further, our results document that plasma LPA levels can exceed 2 μM in mice without apparent ill effects.
We also investigated the ability of Ppap2a tr/tr mice to catabolize LPA by comparing the rate of disappearance of tracer amounts of [ 32 P]LPA from the blood of Ppap2a tr/tr and Ppap2a +/+ animals. We found that [ 32 P]LPA disappears rapidly from the blood of Ppap2a +/+ animals when incubated ex vivo at 37 • C and that this process is even faster in vivo. As Figure 6 documents, Ppap2a tr/tr mice exhibit, both ex vivo and in vivo, a still rapid but distinctly lower rate of LPA disappearance. We have measured only how much LPA remains after injection, so it is not possible to ascribe the disappearance of exogenous LPA to any catabolic process. Nevertheless, the mutant mice demonstrate that LPP1 is in part responsible for this process.
In conclusion, we developed an LPP1 hypomorphic mouse that enabled us to provide a definitive demonstration that LPP1 plays a role in the extracellular catabolism of LPA in intact animals under physiological circumstances. Furthermore, our results suggest a role of LPP1 in controlling the kinetics of extracellular LPA turnover in vivo. These results provide evidence that LPP1 is an important determinant of LPA turnover and circulating LPA concentrations, which might alter LPA signalling patterns.
